DifGen Pharmaceuticals LLC, a global pharmaceutical company with a primary focus on developing complex high barrier to entry generics and specialty pharmaceutical products, completed a U.S. FDA audit of its manufacturing site in Florida, Aveva Drug Delivery systems. This is the first audit after its acquisition of this facility in April 2023. In addition, the company successfully launched its first complex oral sublingual/buccal film – a generic to Suboxone (Buprenoprhine/ Naloxone) in the U....